Regeneron (REGN) Announces EYLEA Phase 2 CAPELLA Missed Primary Endpoint in Neovascular Age-Related Macular Degeneration
Tweet Send to a Friend
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced topline results from the Phase 2 CAPELLA study evaluating aflibercept co-formulated with rinucumab, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
